Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is COMPASS Pathways PLC Sponsored ADR (CMPS) one of those stocks right now? A quick ...

Compass Pathways PLC CMPS said a White House executive order aimed at accelerating mental health treatment research could ...

Fintel reports that on April 24, 2026, B. Riley Securities initiated coverage of COMPASS Pathways plc - Depositary Receipt ...

Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of ...

Investing.com - Compass Pathways plc (NASDAQ:CMPS) said Thursday the U.S. Food and Drug Administration granted the company a rolling New Drug Application review for COMP360, its synthetic psilocybin ...

COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-0.38 EPS, expectations were $-0.37. Operator: Hello, everyone, and welcome to COMPASS Pathways Second Quarter 2025 Earnings ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an invitation for U.S. based ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards ...

COMPASS Pathways PLC ADR research and ratings by Barron's. View CMPS revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

COMPASS Pathways plc misses on earnings expectations. Reported EPS is $-1.44451 EPS, expectations were $-0.4. Operator: Good morning, ladies and gentlemen, and thank you for standing by. My name is ...